Long-Term Quality of Life after Hybrid Robot-assisted and Open Ivor Lewis Esophagectomy for Esophageal Cancer in a Single Center: a Comparative Analysis
Author:
Neuschütz Kerstin J.1, Fourie Lana1, Germann Nicolas2, Pieters Anouk2, Däster Silvio1, Angehrn Fiorenzo V.1, Klasen Jennifer M.1, Müller-Stich Beat P.1, Steinemann Daniel C.1, Bolli Martin1
Affiliation:
1. Clarunis – University Digestive Health Care Center Basel 2. University of Basel
Abstract
Abstract
Purpose
Due to improved survival of esophageal cancer patients, long-term quality of life (QoL) is increasingly gaining importance. We analyzed QoL of patients treated with open Ivor Lewis esophagectomy (Open-E) or a hybrid operation including laparotomy and a robot-assisted thoracic phase (hRob-E), as well as a standard group of healthy individuals.
Methods
With a median follow-up of 36 months after hRob-E (n = 28) and 40 months after Open-E (n = 43), patients´ QoL was assessed using the European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire Core 30 (QLQ-C30) and the EORTC Esophagus specific QoL questionnaire 18 (QLQ-OES18).
Results
Patients showed similar clinical-pathological characteristics, but hRob-E patients had significantly higher ASA scores at surgery (p < 0.001). Patients and healthy controls reported similar global health status, emotional and cognitive functions. However, physical functioning of Open-E patients was significantly reduced compared to healthy controls (p = 0.019). Operated patients reported reduced role and social functioning, fatigue, nausea and vomiting, dyspnea and diarrhea. A trend towards a better pain score after hRob-E compared to Open-E emerged (p = 0.063). Regarding QLQ-OES18, hRob-E and Open-E treated patients similarly reported eating problems, reflux, and troubles swallowing saliva.
Conclusions
The general health status is not impaired after esophagectomy. Despite higher ASA scores, QoL of hRob-E patients is similar to that of patients operated with Open-E. Moreover, patients after hRob-E appear to have a better score regarding physical functioning and a better pain profile than patients after Open-E, indicating a benefit of minimally invasive surgery.
Publisher
Research Square Platform LLC
Reference27 articles.
1. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries;Domper Arnal MJ;World Journal of Gastroenterology,2015 2. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma;Rubenstein JH;Gastroenterology,2015 3. Xu, Q.-L., Li, H., Zhu, Y.-J., & Xu, G. (2020). The treatments and postoperative complications of esophageal cancer: A review. JournalofCardiothoracicSurgery, 15. https://doi.org/10.1186/s13019-020-01202-2 4. Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro,J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven,H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M.A., Blaisse, R. J. B., Busch, O. R., Creemers, G.-J. M., Punt, C. J. A., Plukker,J. T. M., Verheul, H. M. W., … CROSS Study Group. (2021). Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 39(18), 1995–2004. https://doi.org/10.1200/JCO.20.03614 5. Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G.A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch,O. R. C., Ten Kate, F. J. W., Creemers, G.-J. M., Punt, C. J. A., Plukker, J. T. M.,Verheul, H. M. W., Bilgen, E. J. S., … CROSS study group. (2015). Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. The Lancet. Oncology, 16(9), 1090–1098. https://doi.org/10.1016/S1470-2045(15)00040-6
|
|